PHC1: A Drug Target / Disease Biomarker (G1911)

Target Name: PHC1

NCBI ID: G1911

PHC1

PHC1: A Drug Target / Disease Biomarker

PHC1, also known as programmed death-ligand 1, is a protein that is expressed in a variety of tissues throughout the body. It is a cell surface glycoprotein that is involved in cell adhesion, migration, and invasion.PHC1 has also been shown to play a role in cancer progression and has been identified as a potential drug target.

PHC1 is a transmembrane protein that is composed of four distinct domains: an extracellular domain, a transmembrane domain, an intracellular domain, and a C-terminal domain. The extracellular domain is responsible for PHC1's ability to interact with cell surface receptors, while the transmembrane domain is responsible for PHC1's ability to traverse the cell membrane and interact with other proteins on the same membrane. The intracellular domain is responsible for PHC1's ability to interact with intracellular signaling pathways, and the C-terminal domain is responsible for PHC1's ability to interact with other proteins and for its role in cell adhesion and migration.

PHC1 is involved in many different cellular processes, including cell adhesion, migration, and invasion. It is a key regulator of cell-cell adhesion and has been shown to play a role in the development and progression of many types of cancer. For example, PHC1 has been shown to be involved in the development of breast cancer, and high levels of PHC1 have been shown to be associated with poor prognosis in patients with breast cancer.

PHC1 has also been shown to be involved in cell migration and invasion. It has been shown to play a role in the migration of cancer cells through human endothelial cells and has been shown to promote the invasion of cancer cells into human tissue. These findings suggest that PHC1 may be a useful drug target for the treatment of cancer.

In addition to its role in cancer progression, PHC1 has also been shown to play a role in cell signaling pathways. It has been shown to play a role in the signaling pathway that regulates cell proliferation and has been shown to be involved in the regulation of cell apoptosis, or programmed cell death. These findings suggest that PHC1 may be a useful drug target for the treatment of a variety of conditions, including cancer.

PHC1 has also been shown to play a role in the regulation of inflammation. It has been shown to play a role in the regulation of the immune response and has been shown to be involved in the production of inflammatory cytokines. These findings suggest that PHC1 may be a useful drug target for the treatment of a variety of inflammatory conditions.

In conclusion, PHC1 is a protein that is involved in a variety of cellular processes and has been shown to play a role in the development and progression of cancer, cell migration and invasion, and inflammation. As a result, PHC1 is a potential drug target for the treatment of a variety of conditions. Further research is needed to fully understand the role of PHC1 in these processes and to develop effective treatments.

Protein Name: Polyhomeotic Homolog 1

Functions: Component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development. PcG PRC1 complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A 'Lys-119', rendering chromatin heritably changed in its expressibility. Required for proper control of cellular levels of GMNN expression

The "PHC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PHC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets